Loading
Multiple and Secondary Primary Cancers · Journal article
Frontiers in Oncology · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a case report of a colon cancer patient who developed a rare overlapping triad of immune checkpoint inhibitor-induced myocarditis, myositis, and myasthenia gravis-like symptoms with suspected thymic metastasis. The patient responded to corticosteroids, immunoglobulin, and supportive care. The report serves to raise clinical vigilance for this rare syndrome but provides no epidemiological or comparative evidence on incidence, risk stratification, or treatment efficacy.
Case report. One male patient with colon cancer and suspected thymic metastasis receiving immune checkpoint inhibitors. Intervention: Immune checkpoint inhibitor (one cycle); treatment of adverse event with corticosteroids, oxygen therapy, and immunoglobulin. n = 1.
Single male colon cancer patient developed the triad of severe myasthenia gravis, myocarditis, and myositis after one cycle of immune checkpoint inhibitor treatment Symptoms included exertional dyspnea, swallowing weakness, diplopia, dysarthria, limb weakness, and inability to walk due to muscle pain Patient recovered and was discharged after timely administration of corticosteroids, oxygen therapy, and immunoglobulin
No discernible adverse impact on quality of life was observed at follow-up
Clinicians should maintain high suspicion for this rare but severe overlapping triad of myasthenia gravis, myocarditis, and myositis in ICI-treated patients, especially those with thymic masses, presenting with exertional dyspnea, swallowing weakness, or progressive limb weakness. Hospital admission and multidisciplinary team coordination, including consideration of intensive care, is recommended when this syndrome is suspected.
A single uncontrolled case report describing an unusual adverse event triad; raises awareness but provides no comparative data or generalizable evidence on incidence, risk factors, or optimal management.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should maintain high suspicion for this rare but severe overlapping triad of myasthenia gravis, myocarditis, and myositis in ICI-treated patients, especially those with thymic masses, presenting with exertional dyspnea, swallowing weakness, or progressive limb weakness. Hospital admission and multidisciplinary team coordination, including consideration of intensive care, is recommended when this syndrome is suspected.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background The Widespread application of immune checkpoint inhibitors (ICIs) has led to a noticeable increase in patients developing the triad of severe myasthenia gravis (MG), myocarditis, and myositis. However, this overlapping triad syndrome is still very rare, characterized by a subtle onset, a rapid progression, and a high mortality rate. Due to its insidious onset and diagnostic challenges, there is currently limited knowledge of this overlapping triad syndrome in clinical settings. Case presentation We report the case of a male colon cancer patient with suspected thymic metastasis who developed the overlapping immune-related myocarditis, myositis, and MG-like symptoms after one cycle of ICI treatment. The patient received timely administration of corticosteroids, oxygen therapy, immunoglobulin, and other treatments, following which he recovered and was discharged. No discernible adverse impact on his subsequent quality of life was observed. Conclusions Vigilance is warranted for the risk of developing a triad of severe MG, myocarditis, and myositis when patients receiving ICIs present with symptoms such as exertional dyspnea, swallowing weakness, diplopia, dysarthria, limb weakness, or inability to walk due to muscle pain, particularly for patients with thymic masses. Such patients should be monitored in the hospital and, if necessary, admitted to the intensive care unit, where they will be managed by a multidisciplinary team of specialists.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.